TS-021 is a dipeptidyl peptidase 4 (DPP-4) inhibitor potentially for the treatment of type 2 diabetes. TS-021 and/or metformin significantly improved glucose tolerance and glucagon-like peptide-1 (GLP-1) level, and TS-021 alone or in combination with metformin significantly increased the plasma insulin level after nutrient ingestion. In the chronic treatment study, TS-021 in combination with metformin significantly lowered the glycosylated hemoglobin level, plasma insulin level, and α-cell-to-β-cell area ratio in pancreatic islets. TS-021 exhibited a significant improvement in glucose tolerance by increasing the plasma insulin level during orally bioavailable glucose tolerance tests. References: Tajima A, Hirata T, Taniguchi K, Kondo Y, Kato S, Saito-Hori M, Ishimoto T, Yamamoto K. Combination of TS-021 with metformin improves hyperglycemia and synergistically increases pancreatic β-cell mass in a mouse model of type 2 diabetes. Life Sci. 2011 Oct 24;89(17-18):662-70. doi: 10.1016/j.lfs.2011.08.005. PubMed PMID: 21872612.

纯度：≥98%

CAS：667865-69-2